Nuvalent
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
5 of 41
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs loyal emergence from stealth first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent as disclosed third novel program advanced her program towards listed her paper kim kim mila a with potential to deliver multiple transformative catalysts within cash runway window into i a | Nuvalent
Investor Presentation
February 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs my a epee emergence from stealth first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program mined ale me disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Investor Presentation
January 2024
track record of success resource efficient execution and value creation across an expanding portfolio wholly owned programs emergence from first clinical proof of concept second proof of concept first pivotal study disclosed parallel lead programs initiated two global phase studies demonstrated clinical proof of concept and alk for alk program presented preclinical profiles demonstrated clinical proof of concept initiated phase with supporting desired target product for program registrational intent disclosed third novel program advanced her program towards listed her ended with approximately in cash cash equivalents and marketable securities unaudited with potential to deliver multiple transformative catalysts within cash runway window into preliminary unaudited estimate only as the date this presentation subject to change following completion year end closing procedures does not present all information necessary for an understanding financial position as a | Nuvalent
Related slides by other companies
OmniAb
Results
May 2023
active clinical programs and approved products so | OmniAb
Office Properties Income Trust
Mergers and Acquisitions
April 2023
strategic and financial objectives continued focus on increasing cash flows from shop with goal of surpassing by maintain stable cash flows from mob and office properties continue high return investments in properties to maintain market appeal and maximize cash flows target leverage net debt of approximately by year end position business for possible dividend increase in veers a | Office Properties Income Trust
dLocal
Results
May 2023
increased our robust cash position while executing on our share program | dLocal
Limoneira
Investor Day
June 2023
harvest at | Limoneira
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io